Ivera Medical gains licence to BD IV technology
This article was originally published in Clinica
Executive Summary
Medical device manufacturer Ivera Medical has secured exclusive worldwide rights to patents covering intravenous port protector technology belonging to BD (Becton Dickinson). Ivera has gained a licence for issued and pending patents covering technology designed to reduce the potential for healthcare-acquired bloodstream infections. Ivera vice-president of marketing and sales Jack Saladow said that this deal would broaden the San Diego, California company’s existing patent applications and remove any potential patent issues between the two firms. No financial details of the deal were disclosed. Healthcare-acquired bloodstream infections are said to cost the US healthcare system more than $5bn each year.